TMS Co (TSE:4891) Tax Expense: 円0.48 Mil (TTM As of Dec. 2025)


TSE:4891 TMS Co Ltd TSE:4891
32 GF Score
Price 円103.00
! 1 Warning Sign
View Full Analysis

What is TMS Co Tax Expense?

TMS Co TSE:4891 -0.96% 32 Tax Expense is 円0.48 Mil as of Dec. 2025. GuruFocus rates TSE:4891 with a GF Score™ of 32/100. The stock has 1 warning sign investors should review.

TMS Co's tax expense for the months ended in Dec. 2025 was 円0.00 Mil. Its tax expense for the trailing twelve months (TTM) ended in Dec. 2025 was 円0.48 Mil.


TMS Co  (TSE:4891) Tax Expense Explanation

In the long run, income before tax and taxable income will likely be more similar than they are in any given period. If the one is less in earlier years, then it will be greater in later years. Deferred taxes will reverse themselves in the long run and in total will zero out, unless there is something like a change in tax rates in the intervening period. A deferred tax payable results from a tax break in the early years and will reverse itself in later years; a deferred tax receivable results from more taxes being paid in early years than the tax expense reported to shareholders and will again reverse itself in later years. The deferred tax amount is computed by estimating the amount and the timing of the reversal and multiplying that by the appropriate tax rates.


TMS Co Tax Expense Related Terms


TMS Co Tax Expense Historical Data

* Premium members only.

The historical data trend for TMS Co's Tax Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TMS Co Tax Expense Chart

TMS Co Annual Data
Trend Feb21 Feb22 Feb23 Feb24 Feb25
Tax Expense
0.95 2.45 -0.55 0.95 0.95

TMS Co Quarterly Data
Feb21 Feb22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Feb25 May25 Aug25 Dec25
Tax Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.24 0.00 0.24 0.24 0.00
TSE:4891
32GF Score
TMS Co Ltd TSE:4891
Tax Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

TMS Co Tax Expense Calculation

Tax paid by the company. It is computed in by multiplying the income before tax number, as reported to shareholders, by the appropriate tax rate. In reality, the computation is typically considerably more complex due to things such as expenses considered not deductible by taxing authorities ("add backs"), the range of tax rates applicable to various levels of income, different tax rates in different jurisdictions, multiple layers of tax on income, and other issues.

Tax Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was 円0.48 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Tax Expense →
What does a Tax Expense of 円0.48 Mil mean?
TMS Co (TSE:4891) has a Tax Expense of 円0.48 Mil as of Dec. 2025. Tax expense is the amount of tax the company pays in an accounting period. View historical data on TMS Co and its competitors.
Is TMS Co's Tax Expense too high?
TMS Co's current Tax Expense is 円0.48 Mil. Overall, TMS Co has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does TMS Co's Tax Expense compare to VRTX and REGN?
TMS Co's Tax Expense of 円0.48 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tax Expense for a Biotechnology company?
A good Tax Expense depends on the Biotechnology industry context. However, Tax Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tax Expense mean?
A high Tax Expense can signal that a stock is expensive relative to its fundamentals. Tax expense is the amount of tax the company pays in an accounting period. View historical data on TMS Co and its competitors. TMS Co's current Tax Expense is 円0.48 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TMS Co stock overvalued right now?
TMS Co (TSE:4891) has a current Tax Expense of 円0.48 Mil. The current Tax Expense is 円0.48 Mil. TMS Co's overall GF Score™ is 32/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tax Expense calculated?
Tax Expense is calculated from a company's financial statements. For TMS Co (TSE:4891), the current Tax Expense is 円0.48 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TMS Co Business Description

Address 1-9-11F, Fuchu-cho, Fuchu-shi, Tokyo, JPN, 183-0055
TMS Co Ltd is focused on researching, developing, manufacturing, and selling pharmaceuticals. The company is involved in conducting research and development of SMTP compounds, which are drug candidate substances targeting soluble epoxide hydrolase (sEH), an enzyme found in the human body. It is developing sEH inhibitors for various inflammatory diseases. The company's clinical pipeline comprises three compounds: TMS-007 (being developed as a potential treatment for acute cerebral infarction), which is in the late clinical stage, TMS-010, and JX09 (for resistant and poorly controlled hypertension) and TMS-008 (to target acute inflammatory diseases such as kidney injury and cancer cachexia), which are in the early clinical stage. In addition, it has TMS-009 as a backup compound for TMS-008.
32GF Score

Get the complete analysis for TSE:4891

Tax Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

円103.00
Price